Novavax applies for approval to use its Covid-19 vaccine in Singapore_老虎社区_美港股上老虎

Novavax applies for approval to use its Covid-19 vaccine in Singapore

businesstimes2021-11-25

A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA). Confirming this, the authority told ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

SiniS
·2021-11-25
👍🏻
回复
3
举报
Boo2bear
·2021-11-25
Nvax is an old tech. Should be safe than mRNA vax with comparable effectiveness
回复
2
举报
收起
- SiniS:
  👍🏻
  2021-11-25
  回复
  举报
SALLY123
·2021-11-25
ok
回复
4
举报
收起
- Bubble5728:
  [Smile]
  2021-11-25
  回复
  举报
calbee_lwh
·2021-11-25
K
回复
3
举报
balm
·2021-11-25
More options for public
回复
3
举报
收起
- Boo2bear:
  Exactly.
  2021-11-25
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1189493696?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-25 13:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189493696","market":"sg","top_or_hot":-1,"title":"Novavax applies for approval to use its Covid-19 vaccine in Singapore","media":"businesstimes","content":"<div>\n<p>A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore\">网页链接</a>\n\n</div>\n","source":"lsy1607307803821","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax applies for approval to use its Covid-19 vaccine in Singapore</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax applies for approval to use its Covid-19 vaccine in Singapore\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-25 13:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore","article_id":"1189493696","we_media_id":null,"thumbnails":[],"rights":{"source":"lsy1607307803821","url":"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=1189493696","pubTimestamp":1637817970,"sourceInfo":{"source_id":"lsy1607307803821","name":"The Business Times"},"weMediaInfo":null,"summary":"A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied fo","collect":0,"end_time":0,"defaultTopTitle":"businesstimes.com.sg","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"诺瓦瓦克斯医药申请批准在新加波使用其新冠疫苗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told The Straits Times that Novavax had submitted data in its application via the Pandemic Special Access Route on Nov 22.\n\"HSA has commenced a careful and thorough rolling review of the data to ensure that the vaccine meets requirements for quality, safety and efficacy for interim authorisation before it is approved for use in Singapore,\" said its spokesperson.\nShe added that the time taken for the review could range from several weeks to months, depending on the completeness of the data submitted and the time taken by the company to respond to HSA's queries that may surface during regulatory evaluation.\nAccording to the US biotechnology company, clinical trial data compiled from 2 phase 3 trials shows that the non-mRNA vaccine has an efficacy rate of around 90 per cent across a variety of viral variants.\nThe vaccine is given in 2 0.5ml doses, and 21 days apart.\nTrials among 30,000 participants for the vaccine in the United States and Mexico demonstrated 100 per cent protection against moderate and severe disease, and a 90.4 per cent efficacy rate.\nSimilarly, a trial of 15,000 participants in Britain demonstrated an efficacy rate of 96.4 per cent against the original virus strain, 86.3 per cent against the Alpha (B117) variant and 89.7 per cent efficacy overall, said the company.\nNovavax said in response to queries from ST that it is ready to begin delivery of its vaccine doses as soon as it receives \"regulatory authorisation and completion of any release requirements by the authorities\".\nSingapore had signed an advance purchase agreement with the company in January this year to secure supplies of its vaccine.\nHealth Minister Ong Ye Kung had said in June that the Ministry of Health had been looking for good quality vaccines that are safe and effective, to be part of the national vaccination programme.\nAs Novavax is a protein-based vaccine, it uses a laboratory-made version of the Sars-CoV-2 spike protein to stimulate an immune response. Sars-CoV-2 is the virus that causes Covid-19.\nThe supply of the Novavax vaccine would make it the fifth vaccine available here - alongside Pfizer-BioNTech/Comirnaty, Moderna, Sinovac and Sinopharm. Sinopharm has not been included in the national vaccination programme as the manufacturer has not applied for interim approval for use, as at Oct 23.\nAsked about the potential use of the vaccine as a booster, a Novavax spokesperson said that the company's filings to date have been for the vaccine to be used in a primary 2-dose regime.\n\"We expect to apply for additional authorisations following the completion of our booster studies,\" added the spokesperson.\nShe also said that analysis of blood samples from the company's primary vaccine series has shown cross-reactive antibodies to the Alpha, Beta and Delta variants, and these increased six to tenfold with a booster dose.\nData from its recent phase 2 booster study, in which the booster dose was given 6 months after the 2-dose primary series, has shown a 4.6-fold increase in functional antibody levels.\n\"This reinforces our confidence in the potential for a booster dose of the Novavax Covid-19 vaccine to help protect against Covid-19,\" the spokesperson added.\nNovavax and the Serum Institute of India recently received emergency use authorisation for the vaccine to be used in Indonesia and the Philippines.\nThe companies have also filed for the vaccine to be under the World Health Organisation's Emergency Use Listing.","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":874700284,"gmtCreate":1637818841671,"gmtModify":1637818841837,"author":{"id":"3575200115109066","authorId":"3575200115109066","name":"SiniS","avatar":"https://static.tigerbbs.com/6c54fb65b275549d9e3c4b80c5117022","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874700284","repostId":1189493696,"repostType":4,"repost":{"id":"1189493696","pubTimestamp":1637817970,"share":"https://www.laohu8.com/m/news/1189493696?lang=&edition=full","pubTime":"2021-11-25 13:26","market":"us","language":"en","title":"Novavax applies for approval to use its Covid-19 vaccine in Singapore","url":"https://stock-news.laohu8.com/highlight/detail?id=1189493696","media":"businesstimes","summary":"A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied fo","content":"<div>\n<p>A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore\">Web Link</a>\n\n</div>\n","source":"lsy1607307803821","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax applies for approval to use its Covid-19 vaccine in Singapore</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax applies for approval to use its Covid-19 vaccine in Singapore\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-25 13:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189493696","content_text":"A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told The Straits Times that Novavax had submitted data in its application via the Pandemic Special Access Route on Nov 22.\n\"HSA has commenced a careful and thorough rolling review of the data to ensure that the vaccine meets requirements for quality, safety and efficacy for interim authorisation before it is approved for use in Singapore,\" said its spokesperson.\nShe added that the time taken for the review could range from several weeks to months, depending on the completeness of the data submitted and the time taken by the company to respond to HSA's queries that may surface during regulatory evaluation.\nAccording to the US biotechnology company, clinical trial data compiled from 2 phase 3 trials shows that the non-mRNA vaccine has an efficacy rate of around 90 per cent across a variety of viral variants.\nThe vaccine is given in 2 0.5ml doses, and 21 days apart.\nTrials among 30,000 participants for the vaccine in the United States and Mexico demonstrated 100 per cent protection against moderate and severe disease, and a 90.4 per cent efficacy rate.\nSimilarly, a trial of 15,000 participants in Britain demonstrated an efficacy rate of 96.4 per cent against the original virus strain, 86.3 per cent against the Alpha (B117) variant and 89.7 per cent efficacy overall, said the company.\nNovavax said in response to queries from ST that it is ready to begin delivery of its vaccine doses as soon as it receives \"regulatory authorisation and completion of any release requirements by the authorities\".\nSingapore had signed an advance purchase agreement with the company in January this year to secure supplies of its vaccine.\nHealth Minister Ong Ye Kung had said in June that the Ministry of Health had been looking for good quality vaccines that are safe and effective, to be part of the national vaccination programme.\nAs Novavax is a protein-based vaccine, it uses a laboratory-made version of the Sars-CoV-2 spike protein to stimulate an immune response. Sars-CoV-2 is the virus that causes Covid-19.\nThe supply of the Novavax vaccine would make it the fifth vaccine available here - alongside Pfizer-BioNTech/Comirnaty, Moderna, Sinovac and Sinopharm. Sinopharm has not been included in the national vaccination programme as the manufacturer has not applied for interim approval for use, as at Oct 23.\nAsked about the potential use of the vaccine as a booster, a Novavax spokesperson said that the company's filings to date have been for the vaccine to be used in a primary 2-dose regime.\n\"We expect to apply for additional authorisations following the completion of our booster studies,\" added the spokesperson.\nShe also said that analysis of blood samples from the company's primary vaccine series has shown cross-reactive antibodies to the Alpha, Beta and Delta variants, and these increased six to tenfold with a booster dose.\nData from its recent phase 2 booster study, in which the booster dose was given 6 months after the 2-dose primary series, has shown a 4.6-fold increase in functional antibody levels.\n\"This reinforces our confidence in the potential for a booster dose of the Novavax Covid-19 vaccine to help protect against Covid-19,\" the spokesperson added.\nNovavax and the Serum Institute of India recently received emergency use authorisation for the vaccine to be used in Indonesia and the Philippines.\nThe companies have also filed for the vaccine to be under the World Health Organisation's Emergency Use Listing.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874700005,"gmtCreate":1637818706123,"gmtModify":1637818706708,"author":{"id":"3578969648963961","authorId":"3578969648963961","name":"Boo2bear","avatar":"https://static.tigerbbs.com/209ae746c8124fe2d5f79aee784d2fcc","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Nvax is an old tech. Should be safe than mRNA vax with comparable&nbsp;effectiveness","listText":"Nvax is an old tech. Should be safe than mRNA vax with comparable&nbsp;effectiveness","text":"Nvax is an old tech. Should be safe than mRNA vax with comparable effectiveness","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874700005","repostId":1189493696,"repostType":2,"repost":{"id":"1189493696","pubTimestamp":1637817970,"share":"https://www.laohu8.com/m/news/1189493696?lang=&edition=full","pubTime":"2021-11-25 13:26","market":"us","language":"en","title":"Novavax applies for approval to use its Covid-19 vaccine in Singapore","url":"https://stock-news.laohu8.com/highlight/detail?id=1189493696","media":"businesstimes","summary":"A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied fo","content":"<div>\n<p>A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore\">Web Link</a>\n\n</div>\n","source":"lsy1607307803821","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax applies for approval to use its Covid-19 vaccine in Singapore</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax applies for approval to use its Covid-19 vaccine in Singapore\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-25 13:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189493696","content_text":"A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told The Straits Times that Novavax had submitted data in its application via the Pandemic Special Access Route on Nov 22.\n\"HSA has commenced a careful and thorough rolling review of the data to ensure that the vaccine meets requirements for quality, safety and efficacy for interim authorisation before it is approved for use in Singapore,\" said its spokesperson.\nShe added that the time taken for the review could range from several weeks to months, depending on the completeness of the data submitted and the time taken by the company to respond to HSA's queries that may surface during regulatory evaluation.\nAccording to the US biotechnology company, clinical trial data compiled from 2 phase 3 trials shows that the non-mRNA vaccine has an efficacy rate of around 90 per cent across a variety of viral variants.\nThe vaccine is given in 2 0.5ml doses, and 21 days apart.\nTrials among 30,000 participants for the vaccine in the United States and Mexico demonstrated 100 per cent protection against moderate and severe disease, and a 90.4 per cent efficacy rate.\nSimilarly, a trial of 15,000 participants in Britain demonstrated an efficacy rate of 96.4 per cent against the original virus strain, 86.3 per cent against the Alpha (B117) variant and 89.7 per cent efficacy overall, said the company.\nNovavax said in response to queries from ST that it is ready to begin delivery of its vaccine doses as soon as it receives \"regulatory authorisation and completion of any release requirements by the authorities\".\nSingapore had signed an advance purchase agreement with the company in January this year to secure supplies of its vaccine.\nHealth Minister Ong Ye Kung had said in June that the Ministry of Health had been looking for good quality vaccines that are safe and effective, to be part of the national vaccination programme.\nAs Novavax is a protein-based vaccine, it uses a laboratory-made version of the Sars-CoV-2 spike protein to stimulate an immune response. Sars-CoV-2 is the virus that causes Covid-19.\nThe supply of the Novavax vaccine would make it the fifth vaccine available here - alongside Pfizer-BioNTech/Comirnaty, Moderna, Sinovac and Sinopharm. Sinopharm has not been included in the national vaccination programme as the manufacturer has not applied for interim approval for use, as at Oct 23.\nAsked about the potential use of the vaccine as a booster, a Novavax spokesperson said that the company's filings to date have been for the vaccine to be used in a primary 2-dose regime.\n\"We expect to apply for additional authorisations following the completion of our booster studies,\" added the spokesperson.\nShe also said that analysis of blood samples from the company's primary vaccine series has shown cross-reactive antibodies to the Alpha, Beta and Delta variants, and these increased six to tenfold with a booster dose.\nData from its recent phase 2 booster study, in which the booster dose was given 6 months after the 2-dose primary series, has shown a 4.6-fold increase in functional antibody levels.\n\"This reinforces our confidence in the potential for a booster dose of the Novavax Covid-19 vaccine to help protect against Covid-19,\" the spokesperson added.\nNovavax and the Serum Institute of India recently received emergency use authorisation for the vaccine to be used in Indonesia and the Philippines.\nThe companies have also filed for the vaccine to be under the World Health Organisation's Emergency Use Listing.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6718509,"gmtCreate":1637818830266,"gmtModify":1637818830363,"authorId":3575200115109066,"author":{"id":3575200115109066,"authorId":3575200115109066,"name":"SiniS","avatar":"https://static.tigerbbs.com/6c54fb65b275549d9e3c4b80c5117022","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874700005,"type":1,"supId":0,"prevId":0,"content":"👍🏻","text":"👍🏻","html":"👍🏻"}],"langContent":"CN"},{"id":874477279,"gmtCreate":1637818608589,"gmtModify":1637818608726,"author":{"id":"3586512925725941","authorId":"3586512925725941","name":"SALLY123","avatar":"https://static.tigerbbs.com/3645082e74bb8034e0163391e44f18e8","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874477279","repostId":1189493696,"repostType":4,"repost":{"id":"1189493696","pubTimestamp":1637817970,"share":"https://www.laohu8.com/m/news/1189493696?lang=&edition=full","pubTime":"2021-11-25 13:26","market":"us","language":"en","title":"Novavax applies for approval to use its Covid-19 vaccine in Singapore","url":"https://stock-news.laohu8.com/highlight/detail?id=1189493696","media":"businesstimes","summary":"A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied fo","content":"<div>\n<p>A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore\">Web Link</a>\n\n</div>\n","source":"lsy1607307803821","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax applies for approval to use its Covid-19 vaccine in Singapore</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax applies for approval to use its Covid-19 vaccine in Singapore\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-25 13:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189493696","content_text":"A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told The Straits Times that Novavax had submitted data in its application via the Pandemic Special Access Route on Nov 22.\n\"HSA has commenced a careful and thorough rolling review of the data to ensure that the vaccine meets requirements for quality, safety and efficacy for interim authorisation before it is approved for use in Singapore,\" said its spokesperson.\nShe added that the time taken for the review could range from several weeks to months, depending on the completeness of the data submitted and the time taken by the company to respond to HSA's queries that may surface during regulatory evaluation.\nAccording to the US biotechnology company, clinical trial data compiled from 2 phase 3 trials shows that the non-mRNA vaccine has an efficacy rate of around 90 per cent across a variety of viral variants.\nThe vaccine is given in 2 0.5ml doses, and 21 days apart.\nTrials among 30,000 participants for the vaccine in the United States and Mexico demonstrated 100 per cent protection against moderate and severe disease, and a 90.4 per cent efficacy rate.\nSimilarly, a trial of 15,000 participants in Britain demonstrated an efficacy rate of 96.4 per cent against the original virus strain, 86.3 per cent against the Alpha (B117) variant and 89.7 per cent efficacy overall, said the company.\nNovavax said in response to queries from ST that it is ready to begin delivery of its vaccine doses as soon as it receives \"regulatory authorisation and completion of any release requirements by the authorities\".\nSingapore had signed an advance purchase agreement with the company in January this year to secure supplies of its vaccine.\nHealth Minister Ong Ye Kung had said in June that the Ministry of Health had been looking for good quality vaccines that are safe and effective, to be part of the national vaccination programme.\nAs Novavax is a protein-based vaccine, it uses a laboratory-made version of the Sars-CoV-2 spike protein to stimulate an immune response. Sars-CoV-2 is the virus that causes Covid-19.\nThe supply of the Novavax vaccine would make it the fifth vaccine available here - alongside Pfizer-BioNTech/Comirnaty, Moderna, Sinovac and Sinopharm. Sinopharm has not been included in the national vaccination programme as the manufacturer has not applied for interim approval for use, as at Oct 23.\nAsked about the potential use of the vaccine as a booster, a Novavax spokesperson said that the company's filings to date have been for the vaccine to be used in a primary 2-dose regime.\n\"We expect to apply for additional authorisations following the completion of our booster studies,\" added the spokesperson.\nShe also said that analysis of blood samples from the company's primary vaccine series has shown cross-reactive antibodies to the Alpha, Beta and Delta variants, and these increased six to tenfold with a booster dose.\nData from its recent phase 2 booster study, in which the booster dose was given 6 months after the 2-dose primary series, has shown a 4.6-fold increase in functional antibody levels.\n\"This reinforces our confidence in the potential for a booster dose of the Novavax Covid-19 vaccine to help protect against Covid-19,\" the spokesperson added.\nNovavax and the Serum Institute of India recently received emergency use authorisation for the vaccine to be used in Indonesia and the Philippines.\nThe companies have also filed for the vaccine to be under the World Health Organisation's Emergency Use Listing.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6718662,"gmtCreate":1637819729298,"gmtModify":1637819729329,"authorId":3575454990112554,"author":{"id":3575454990112554,"authorId":3575454990112554,"name":"Bubble5728","avatar":"https://static.tigerbbs.com/ffe6f8385b6f65785cb6f3337622382d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874477279,"type":1,"supId":0,"prevId":0,"content":"[Smile]","text":"[Smile]","html":"[Smile]"}],"langContent":"CN"},{"id":874477082,"gmtCreate":1637818458100,"gmtModify":1637818458270,"author":{"id":"3579950492873390","authorId":"3579950492873390","name":"calbee_lwh","avatar":"https://static.tigerbbs.com/2c71feed0eaf38825c4f2fc86cd7a84d","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874477082","repostId":1189493696,"repostType":4,"repost":{"id":"1189493696","pubTimestamp":1637817970,"share":"https://www.laohu8.com/m/news/1189493696?lang=&edition=full","pubTime":"2021-11-25 13:26","market":"us","language":"en","title":"Novavax applies for approval to use its Covid-19 vaccine in Singapore","url":"https://stock-news.laohu8.com/highlight/detail?id=1189493696","media":"businesstimes","summary":"A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied fo","content":"<div>\n<p>A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore\">Web Link</a>\n\n</div>\n","source":"lsy1607307803821","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax applies for approval to use its Covid-19 vaccine in Singapore</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax applies for approval to use its Covid-19 vaccine in Singapore\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-25 13:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189493696","content_text":"A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told The Straits Times that Novavax had submitted data in its application via the Pandemic Special Access Route on Nov 22.\n\"HSA has commenced a careful and thorough rolling review of the data to ensure that the vaccine meets requirements for quality, safety and efficacy for interim authorisation before it is approved for use in Singapore,\" said its spokesperson.\nShe added that the time taken for the review could range from several weeks to months, depending on the completeness of the data submitted and the time taken by the company to respond to HSA's queries that may surface during regulatory evaluation.\nAccording to the US biotechnology company, clinical trial data compiled from 2 phase 3 trials shows that the non-mRNA vaccine has an efficacy rate of around 90 per cent across a variety of viral variants.\nThe vaccine is given in 2 0.5ml doses, and 21 days apart.\nTrials among 30,000 participants for the vaccine in the United States and Mexico demonstrated 100 per cent protection against moderate and severe disease, and a 90.4 per cent efficacy rate.\nSimilarly, a trial of 15,000 participants in Britain demonstrated an efficacy rate of 96.4 per cent against the original virus strain, 86.3 per cent against the Alpha (B117) variant and 89.7 per cent efficacy overall, said the company.\nNovavax said in response to queries from ST that it is ready to begin delivery of its vaccine doses as soon as it receives \"regulatory authorisation and completion of any release requirements by the authorities\".\nSingapore had signed an advance purchase agreement with the company in January this year to secure supplies of its vaccine.\nHealth Minister Ong Ye Kung had said in June that the Ministry of Health had been looking for good quality vaccines that are safe and effective, to be part of the national vaccination programme.\nAs Novavax is a protein-based vaccine, it uses a laboratory-made version of the Sars-CoV-2 spike protein to stimulate an immune response. Sars-CoV-2 is the virus that causes Covid-19.\nThe supply of the Novavax vaccine would make it the fifth vaccine available here - alongside Pfizer-BioNTech/Comirnaty, Moderna, Sinovac and Sinopharm. Sinopharm has not been included in the national vaccination programme as the manufacturer has not applied for interim approval for use, as at Oct 23.\nAsked about the potential use of the vaccine as a booster, a Novavax spokesperson said that the company's filings to date have been for the vaccine to be used in a primary 2-dose regime.\n\"We expect to apply for additional authorisations following the completion of our booster studies,\" added the spokesperson.\nShe also said that analysis of blood samples from the company's primary vaccine series has shown cross-reactive antibodies to the Alpha, Beta and Delta variants, and these increased six to tenfold with a booster dose.\nData from its recent phase 2 booster study, in which the booster dose was given 6 months after the 2-dose primary series, has shown a 4.6-fold increase in functional antibody levels.\n\"This reinforces our confidence in the potential for a booster dose of the Novavax Covid-19 vaccine to help protect against Covid-19,\" the spokesperson added.\nNovavax and the Serum Institute of India recently received emergency use authorisation for the vaccine to be used in Indonesia and the Philippines.\nThe companies have also filed for the vaccine to be under the World Health Organisation's Emergency Use Listing.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874474967,"gmtCreate":1637818334000,"gmtModify":1637818334122,"author":{"id":"3563672045211925","authorId":"3563672045211925","name":"balm","avatar":"https://static.tigerbbs.com/0b3156e053d7ec11324d42163b84c2d1","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"More options for public","listText":"More options for public","text":"More options for public","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874474967","repostId":1189493696,"repostType":2,"repost":{"id":"1189493696","pubTimestamp":1637817970,"share":"https://www.laohu8.com/m/news/1189493696?lang=&edition=full","pubTime":"2021-11-25 13:26","market":"us","language":"en","title":"Novavax applies for approval to use its Covid-19 vaccine in Singapore","url":"https://stock-news.laohu8.com/highlight/detail?id=1189493696","media":"businesstimes","summary":"A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied fo","content":"<div>\n<p>A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore\">Web Link</a>\n\n</div>\n","source":"lsy1607307803821","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax applies for approval to use its Covid-19 vaccine in Singapore</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax applies for approval to use its Covid-19 vaccine in Singapore\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-25 13:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.businesstimes.com.sg/government-economy/novavax-applies-for-approval-to-use-its-covid-19-vaccine-in-singapore","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189493696","content_text":"A new Covid-19 vaccine could be available in Singapore, with American firm Novavax having applied for interim authorisation by the Health Sciences Authority (HSA).\nConfirming this, the authority told The Straits Times that Novavax had submitted data in its application via the Pandemic Special Access Route on Nov 22.\n\"HSA has commenced a careful and thorough rolling review of the data to ensure that the vaccine meets requirements for quality, safety and efficacy for interim authorisation before it is approved for use in Singapore,\" said its spokesperson.\nShe added that the time taken for the review could range from several weeks to months, depending on the completeness of the data submitted and the time taken by the company to respond to HSA's queries that may surface during regulatory evaluation.\nAccording to the US biotechnology company, clinical trial data compiled from 2 phase 3 trials shows that the non-mRNA vaccine has an efficacy rate of around 90 per cent across a variety of viral variants.\nThe vaccine is given in 2 0.5ml doses, and 21 days apart.\nTrials among 30,000 participants for the vaccine in the United States and Mexico demonstrated 100 per cent protection against moderate and severe disease, and a 90.4 per cent efficacy rate.\nSimilarly, a trial of 15,000 participants in Britain demonstrated an efficacy rate of 96.4 per cent against the original virus strain, 86.3 per cent against the Alpha (B117) variant and 89.7 per cent efficacy overall, said the company.\nNovavax said in response to queries from ST that it is ready to begin delivery of its vaccine doses as soon as it receives \"regulatory authorisation and completion of any release requirements by the authorities\".\nSingapore had signed an advance purchase agreement with the company in January this year to secure supplies of its vaccine.\nHealth Minister Ong Ye Kung had said in June that the Ministry of Health had been looking for good quality vaccines that are safe and effective, to be part of the national vaccination programme.\nAs Novavax is a protein-based vaccine, it uses a laboratory-made version of the Sars-CoV-2 spike protein to stimulate an immune response. Sars-CoV-2 is the virus that causes Covid-19.\nThe supply of the Novavax vaccine would make it the fifth vaccine available here - alongside Pfizer-BioNTech/Comirnaty, Moderna, Sinovac and Sinopharm. Sinopharm has not been included in the national vaccination programme as the manufacturer has not applied for interim approval for use, as at Oct 23.\nAsked about the potential use of the vaccine as a booster, a Novavax spokesperson said that the company's filings to date have been for the vaccine to be used in a primary 2-dose regime.\n\"We expect to apply for additional authorisations following the completion of our booster studies,\" added the spokesperson.\nShe also said that analysis of blood samples from the company's primary vaccine series has shown cross-reactive antibodies to the Alpha, Beta and Delta variants, and these increased six to tenfold with a booster dose.\nData from its recent phase 2 booster study, in which the booster dose was given 6 months after the 2-dose primary series, has shown a 4.6-fold increase in functional antibody levels.\n\"This reinforces our confidence in the potential for a booster dose of the Novavax Covid-19 vaccine to help protect against Covid-19,\" the spokesperson added.\nNovavax and the Serum Institute of India recently received emergency use authorisation for the vaccine to be used in Indonesia and the Philippines.\nThe companies have also filed for the vaccine to be under the World Health Organisation's Emergency Use Listing.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6718418,"gmtCreate":1637818460583,"gmtModify":1637818460680,"authorId":3578969648963961,"author":{"id":3578969648963961,"authorId":3578969648963961,"name":"Boo2bear","avatar":"https://static.tigerbbs.com/209ae746c8124fe2d5f79aee784d2fcc","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874474967,"type":1,"supId":0,"prevId":0,"content":"Exactly.","text":"Exactly.","html":"Exactly."}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":43,"commentSize":5,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}